

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  53D0056408	<b>(X3) Date Survey Completed</b>  08/12/2019
<b>Name of Provider or Supplier</b>  South Lincoln Hospital District	<b>Street Address, City, State</b>  711 Onyx Street, Kemmerer, WY	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D2016</b>	<p><b>SUCCESSFUL PARTICIPATION</b> CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on American Proficiency Institute (API) report review, e-mail confirmation of test results, and CASPER 153 and 155 reports review, the laboratory failed to successfully participate in 2 of 3 proficiency testing events for the Digoxin analyte (API event 3 of 2018 and API event 2 of 2019). (See D2118.)</p>
<b>D2118</b>	<p><b>TOXICOLOGY</b> CFR(s): 493.845(f)</p> <p>Failure to achieve satisfactory performance for the same analyte or test in two</p>

consecutive testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on American Proficiency Institute (API) report review, CASPER 153 and 155 reports review, and e-mail confirmation of test results, the laboratory failed to successfully participate in 2 consecutive proficiency testing events for the Digoxin analyte (API event 3 of 2018 and API event 2 of 2019). Findings include: 1. API summary evaluation reports review for the second chemistry proficiency testing event of 2019 included a summary score of 0% for Digoxin analyte tests and 60% score for Digoxin analyte testing performed for the 3rd event of 2018. 2. Casper reports for 2 out of 3 events reviewed included Digoxin scores of 0% for the 2nd event of 2019 and 60% for the 3rd event of 2018. 3. In an e-mail interview conducted on 08/12/2019 the laboratory staff confirmed the laboratory scores of 60% and 0% for Digoxin proficiency tests scores in the 3rd event of 2018 and the 2nd event of 2019 respectively.